Progyny(US:PGNY) Yahoo Finance·2025-10-22 20:55分组1: Federal Layoffs and Biotech Industry Impact - Federal budget cuts and government shutdown are affecting various health agencies, notably the FDA, which is crucial for biotech companies [2][3] - The FDA is largely funded by user fees, allowing 86% of its employees to remain active during the shutdown, but new drug applications requiring user fees cannot be accepted [2][3] - NIH budget cuts are impacting early-stage research, which is vital for innovation in the biotech sector, although there are efforts to restore funding [4] 分组2: The Trade Desk - The Trade Desk has seen a significant decline of 63% since its peak, attributed to missed earnings guidance and revenue growth slowing below 20% for the first time as a public company [8][9] - Despite challenges, The Trade Desk is still positioned in a $935 billion digital advertising market, with a reasonable valuation at less than 25 times forward earnings [9] - The company is expected to continue gaining market share, even as revenue growth slows [9] 分组3: Bristol Myers Squibb - Bristol Myers Squibb is facing challenges due to a significant patent cliff, particularly with drugs like Eliquis, which will face generic competition [12][13] - The company is projected to have earnings per share around $6.50 and revenue of approximately $47 billion, resulting in a low PE multiple of less than seven [12][13] - Despite expected declines in profits and revenue, the company has a strong history of paying dividends, currently yielding around 5.6% [13][15] 分组4: Progyny - Progyny has experienced a 41% decline in stock price, but its services for infertility are becoming increasingly important, with a growing client base of self-insured companies [16][17] - Revenue growth was 9.5% in the most recent quarter, with gross profit increasing by 16%, indicating improved efficiency [16][17] - The company is expanding its services, including menopause support, which has received positive initial feedback from clients [17][18]